|Articles|June 1, 2015
- Applied Clinical Trials-06-01-2015
- Volume 24
- Issue 6
Oncology Leads Personalized Medicine
Author(s)Tufts, CSDD
Study finds that almost 75% of cancer drug candidates rely on biomarker data.
Advertisement
The opportunity to more precisely target and to personalize medical treatments based on biomarker data has attracted growing interest from biopharmaceutical companies. A recent study by the Tufts Center for the Study of Drug
Development (Tufts CSDD) finds that oncology dominates personalized medicine product development in part because cancer-related illnesses are extremely complex and they receive the highest level of R&D activity. Companies involved in developing personalized medicines report that across all phases, 73% of oncology drugs now rely on biomarker data. This compares with 42% of compounds in all indications.
- Tufts CSDD
Articles in this issue
about 11 years ago
FDA Seeks Resources to Support New Research Initiativesabout 11 years ago
Safety Considerations for Follow-On Non-Biologic Complex Drugsabout 11 years ago
Putting the EMA House in Orderabout 11 years ago
Experts Call for Urgent Action on Antibiotics Researchabout 11 years ago
Characterizing the Real Cost of Site Regulatory Complianceabout 11 years ago
Using 505(b)(2) to Solve Shortfall from Generic Cliffabout 11 years ago
Lifecycle Modeling and Simulation in Clinical Trialsabout 11 years ago
The U.S. Biosimilar Pathway: Policy Precedes Scienceabout 11 years ago
Managing Portfolios for Economic and Clinical Valueabout 11 years ago
Applied Clinical Trials Digital Edition - June/July 2015Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Agentic RTSM and the Push to Compress Clinical Trial Startup: Q&A with Robert Hummel, Suvoda
2
AI-Driven Clinical Trial Recruitment and Design
3
Why Clinical Trials Need an Execution Architecture Before AI Can Deliver: Q&A with Abraham Gutman, AG Mednet
4
How RBQM Needs to Evolve for a Real-Time Oversight World
5